Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 2 Sep
Source: Bse
Medi Assist Healthcare Services Limited (MEDIASSIST)
Small CapPharma stocks · Small cap · NSE
Medi Assist Healthcare Services Limited operates in Health Insurance TPA, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result16 Aug, 01:50 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
54Neutralfull bear SMA stack · SMA20 -7.8% / mo · MACD + · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 24
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
MEDIASSISTD candles · FIT view-18.9%Latest close ₹292.90 on 2026-10-21
Bar
-1.2%
RSI
35
MACD hist
0.64
52W pos
2%
2026-10-21O ₹296.45H ₹299.00L ₹286.05C ₹292.90Vol 1.9L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
MEDIASSISTNifty PharmaNifty 500
- MEDIASSIST
- -18.0%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -11.5 pp
Chart stats
21 Oct 2026- From 52W high
- -49.1%
- 52W range position
- 2%
- ATR (14)
- 3.7%
- Volume vs 20D
- 0.71x
- Avg traded value
- ₹7.6 Cr
- 20D price channel
- ₹286.1 - ₹342.9
₹575.6
₹286.1 - ₹575.6
₹10.9
Latest completed session
20-session average
30.3% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE50
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average52
Revenue +24.1% · PAT +21.7% YoY
Technical
Neutral54
Price trend and sector-relative-strength timing.
Valuation
Legacy model+48.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence70
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 52/100margin compression · Rev +24% YoY · PAT +22% YoY
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹237 Cr | +24.1% | -2.1% |
| EBITDA | ₹48 Cr | +14.3% | +0.0% |
| Operating margin | 20.0% | -200 bps | +0 bps |
| PAT | ₹28 Cr | +21.7% | -48.1% |
| PAT margin | 11.8% | -23 bps | -1050 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 22.50
- P/B
- 2.65
- EV/EBITDA
- 8.55
- Market Cap
- 2220.00Cr
Profitability
- ROE
- 13.40%
- ROCE
- 13.20%
- ROA
- 6.85%
- Dividend Y
- 0.67%
Growth (CAGR)
- Revenue 5Y
- 23.00%
- EPS 5Y
- 31.00%
- Revenue 3Y
- 21.00%
- EPS 3Y
- 10.00%
Balance Sheet
- Debt/Equity
- 0.06
- Interest Coverage
- 9.05×
- Altman Z
- 4.67
- Book Value
- 112.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 4/5
- OCF
- 118.00 Cr
- EPS TTM
- 12.56
Shareholding
- Promoter Hold
- 4.61%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 2%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 237-2.1% vs prev
Net Profit
₹ CrLatest: 28.0-48.1% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 35.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~8.5% over last month) — short-term momentum negative.
- RSI(14) at 35 — falling, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
14
RS percentile
Stage 4 Downtrend
1M return
-13.0%
3M return
-18.0%
6M return
-19.4%
1Y return
-47.2%
RS 1D
+1
RS 20D
-9
Sector rank
#1
Industry rank
#14
Stage evidence
- Price is 15.5% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.3%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 57.49-1.37%
RS vs Nifty 50057
Valuation & peers
U-Score 50 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 50 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Financial Turnaround
Fundamental score breakdown
U band · FAIR VALUEValuation14/30
Growth16/25
Quality1/20
Balance Sheet9/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
50
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
50/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 48.2%.
- Growth contributes 16/25 to the score.
Main drags
- Quality is weaker at 1/20; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
- Valuation is weaker at 14/30; verify the latest quarterly trend.
Sector valuation model
Insurance valuation: embedded value and VNB quality
Insurance economics depend on long-duration book value and new-business profitability.
Primary lens
P/embedded value where available, plus VNB growth and margin.
Secondary checks
Persistency, product mix, solvency, distribution strength.
Main risk check
Accounting profit is less useful than embedded value quality.
PE
22.5
PB
2.6
EV/EBITDA
8.6
ROE
13.4%
ROCE
13.2%
FCF Yield
—
Debt/Equity
0.1
MoS
+48.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
50
Previous: 50
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+48.2%
Previous: +47.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
50
50
50
50
50
50
50
50
50
50
50
50
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹177.91
-64.6% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹565.2
+48.2% MoS
PEG
1.00
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
MAXIND
Small
Max India Limited
Healthcare Services
match 132
24
—
-32.8%
—
OVERVALUED
CANHLIFE
Large
Canara HSBC Life Insurance Company Limited
Insurance
match 58
20
95.7
8.1%
-545%
OVERVALUED
SAKAR
Small
Sakar Healthcare Limited
Healthcare Services
match 14
38
62.1
10.0%
-26%
WATCHLIST
SYNCOMF
Small
Syncom Formulations (India) Limited
Healthcare Services
match 13
66
25.4
17.6%
+48%
UNDERVALUED
FISCHER
Small
Fischer Medical Ventures Limited
Healthcare Services
match 13
30
93.6
8.9%
-65%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Medi Assist Healthcare Services Limited operates in Health Insurance TPA, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
70Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: financial discipline is weak at 58/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
49 docs text-extracted · 22 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
63rd percentile
overall median 67 · Pharma: 50th pctile, median 70 · Small: 65th pctile, median 66
Evidence depth
Financial-only
49 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
66
acceptable · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
58
watch · capital discipline
Results
61
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4 years of positive FCF.
- ▸Debt/equity is 0.06.
- ▸4/4 latest quarters had positive YoY revenue growth.
Trust risks
- ▸2 latest quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding is only 4.6%.
- ▸ROCE trend is -4.6%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Medi Assist Healthcare Services Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 12 Aug - Newspaper advertisement relating to 26th AGM and record date for payment of final dividend for the FY 2025-26
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Aug - Q1 FY27 revenue rose 24.1% to ₹236.5 Cr; AI contracts signed, Mayfair ownership increased.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Acquisition 24 Jun - Board approved GBP 589,270 to raise Mayfair We Care stake from 60% to 91.75%.
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
Investor presentationMay 2026
May 2026 · PPT
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Press Release / Media Release 10 May - Medi Assist reports FY26 revenue up 25.1%, becomes debt-free, with ₹904.8 Cr revenue and ₹174.6 Cr EBITDA.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.